SERT occupancies and serum drug concentrations after in utero exposure and postnatal clearance
| Drug | Litter | E21 | PNC3 | PNC7 | PNC14 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Occupancy Pups (mean ± S.E.M.) | Pup Drug AF Concentration | Dam Drug Serum Concentration. | Occupancy Pups (mean ± S.E.M.) | Pup Drug Serum Concentration | Dam Drug Serum Concentration | Occupancy Pups (mean ± S.E.M.) | Pup Drug Serum Concentration | Dam Drug Serum Concentration | Occupancy Pups (mean ± S.E.M.) | Pup Drug Serum Concentration | Dam Drug Serum Concentration | ||
| % | ng/ml | % | ng/ml | % | ng/ml | % | ng/ml | ||||||
| Sertraline | |||||||||||||
| Median | 1 | 93.8 ± 1.3*** | <2/<2 | 28.8/130.7 | 13.9 ± 19.0 | −21.02 ± 8.72 | |||||||
| Median | 2 | 92.8 ± 2.9*** | <2/<2 | 29.1/43.16 | −7.8 ± 4.8 | 17.68 ± 11.49 | |||||||
| High | 3 | 85.3 ± 2.2*** | <2/<2 | 143/21 | 9.1 ± 2.6 | −10.28 ± 9.5 | |||||||
| High | 4 | 82.1 ± 4.0*** | <2/<2 | 202/76 | 45.8 ± 8.6** | −21.13 ± 18.7 | |||||||
| Paroxetine | |||||||||||||
| Median | 1 | 97.9 ± 0.6*** | <2 | 63 | −12.22 ± 4.4 | <2 | 33 | −17.1 ± 7.2 | <2 | 111 | |||
| Median | 2 | 97.5 ± 0.4*** | <2 | 24 | 11.8 ± 2.1 | 30 | 66 | −12.2 ± 2.7 | <2 | 89 | |||
| High | 3 | 96.8 ± 0.8*** | <2 | 110 | 25.1 ± 3.3 | 24 | 68 | ||||||
| High | 4 | 99.2 ± 0.2*** | 3 | 132 | |||||||||
| Fluoxetine | |||||||||||||
| Median | 1 | 100.0 ± 0.0*** | <2/152 | 148/265 | 40.8 ± 1.8*** | 34/20 | 40/166 | 9.1 ± 5.1 | <2/<2 | 48/439 | 9.7 ± 7.0 | 10/50 | 84/484 |
| Median | 2 | 98.2 ± 1.0*** | <2/158 | 119/216 | 74.2 ± 0.6*** | 68/60 | 44/309 | −20.3 ± 4.2** | <2/<2 | 42/414 | 11.1 ± 5.6** | 18/32 | 18/263 |
| High | 3 | 96.2 ± 1.6*** | Lost | 224/741 | 91.5 ± 0.4*** | 58/64 | 96/480 | −33.3 ± 6.6** | <2/<2 | 70/620 | 5.2 ± 6.4 | 10/19 | 108/576 |
| High | 4 | 100.0 ± 0.0*** | 28/167 | 168/593 | 88.1 ± 0.4*** | 67/66 | 144/886 | 40.2 ± 6.8*** | <2/10 | 132/668 | 3.7 ± 3.2 | 2/12 | 280/548 |
| Venlafaxine | |||||||||||||
| Median | 1 | 64.5 ± 6.1*** | 66/201 | 49/350 | 1.5 ± 3.0 | <2/<2 | 210/51 | −14.96 ± 4.6 | <2/<2 | 65/358 | |||
| Median | 2 | 60.9 ± 6.9*** | 81/344 | 72/537 | 1.3 ± 1.2 | <2/<2 | 236/80 | 11.2 ± 18.0 | <2/<2 | 35/255 | |||
| High | 3 | 70.1 ± 2.2*** | 82/476 | 111/702 | 14.3 ± 6.6 | <2/<2 | 327/67 | 5.7 ± 6.0 | <2/<2 | 63/522 | |||
| High | 4 | 92.0 ± 2.1*** | 120/344 | 232/1002 | 5.4 ± 0.5 | <2/<2 | 348/81 | 0.3 ± 2.3 | <2/<2 | 147/941 | |||
| High | 5 | 71.6 ± 3.1*** | 164/475 | 177/692 | 9.1 ± 3.4 | <2/<2 | 408/62 | ||||||
| Escitalopram | |||||||||||||
| Median | 1 | 85.0 ± 2.1*** | 18 | 20 | 6.2 ± 6.5 | <2 | 21 | 41.1 ± 3.7*** | <2 | 39 | |||
| Median | 2 | 89.9 ± 5.0*** | 15 | 23 | −9.3 ± 7.6 | <2 | 37 | 31.0 ± 4.4*** | <2 | 21 | |||
| High | 3 | 92.0 ± 1.3*** | Lost | 54 | −11.7 ± 1.5 | <2 | 74 | 3.9 ± 3.5 | <2 | 75 | |||
| High | 4 | 96.8 ± 0.2*** | Lost | 52 | 2.3 ± 5.4 | <2 | 88 | 1.4 ± 3.7 | <2 | 43 | |||
** , p < 0.01;
*** , p < 0.001.